Evidence map›Paper›PMID 24594868›Full record

ArticleBMJ (Clinical research ed.)2014

Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study.

Alexi A Wright, Baohui Zhang, Nancy L Keating, Jane C Weeks, Holly G Prigerson

2 registry-linked trialsOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in BMJ (Clinical research ed.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 136 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
136citing papers in PubMed, 4 pooled it
40.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04158908 completednot on this mapstarted 2020, after this paper: background citation

Giving Information Systematically and Transparently in Lung and GI Cancer

TypeobservationalSponsorWeill Medical College of Cornell UniversityRan2020 to 2020Enrolled20ConditionsCritical Illness, Oncology, CommunicationArmsOncolo-GIST
NCT04179305 nacompletednot on this mapstarted 2020, after this paper: background citation

Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2

TypeinterventionalSponsorWeill Medical College of Cornell UniversityRan2020 to 2023Enrolled37ConditionsCritical Illness, Oncology, CommunicationArmsOncolo-GIST, Usual Care Arm
3 · Its place in the literature

Who cites it

136 citing papers in PubMed, 4 syntheses or guidelines pooled it, 336 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. End-of-Life Preferences: A Randomized Trial of Framing Comfort Care as Refusal of Treatment in the Context of COVID-19.Medical decision making : an international journal of the Society for Medical Decision Making · 2023
    Trial
  7. Trial
  8. Trial
  9. Classification of a palliative care population in a comprehensive cancer centre.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Dyadic-concordance death-preparedness states and end-of-life care received by cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Scoping review of anticancer drug utilization in lung cancer patients at the end of life.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article

76 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Alexi A WrightHarvard Medical School, Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 1133, 450 Brookline Avenue, Boston, MA 02215, USA.
Baohui Zhang
Nancy L Keating
Jane C Weeks
Holly G Prigerson
Cornell University · USDana-Farber Cancer Institute · USHarvard University · US

Funding

U Mass Boston / DFHCC U54 Partnership (1 of 2)U54CA156732 · NCI · DANA-FARBER CANCER INST · PI KASISOMAYAJULA VISWANATH · 2010 to 2026
$25.6M
Quality of Death: Ethnic and Psychosocial InfluencesR01CA106370 · NCI · YALE UNIVERSITY · PI PRIGERSON, HOLLY GWEN · 2004 to 2015
$4.1M
Psychiatric Disorder in Dying Patients &Their SurvivorsR01MH063892 · NIMH · YALE UNIVERSITY · PI JACOBS, SELBY C · 2002 to 2005
$1.9M
Explaining Variations in End-of-Life Care IntensityR01CA164021 · NCI · HARVARD MEDICAL SCHOOL · PI KEATING, NANCY L · 2012 to 2014
$1.6M
Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian CancerK07CA166210 · NCI · DANA-FARBER CANCER INST · PI WRIGHT, ALEXI A · 2013 to 2017
$886k
NCI NIH HHS 1K07 CA166210NCI NIH HHS 1R01 CA164021NCI NIH HHS CA 106370NCI NIH HHS CA 156732NCI NIH HHS K07 CA166210NCI NIH HHS R01 CA164021NCI NIH HHS U54 CA156732NIMH NIH HHS MH63892
6 · The paper itself

Abstract

objectivesTo determine whether the receipt of chemotherapy among terminally ill cancer patients months before death was associated with patients' subsequent intensive medical care and place of death.

designSecondary analysis of a prospective, multi-institution, longitudinal study of patients with advanced cancer.

settingEight outpatient oncology clinics in the United States.

participants386 adult patients with metastatic cancers refractory to at least one chemotherapy regimen, whom physicians identified as terminally ill at study enrollment and who subsequently died.

main outcome measuresPRIMARY OUTCOMES: intensive medical care (cardiopulmonary resuscitation, mechanical ventilation, or both) in the last week of life and patients' place of death (for example, intensive care unit). SECONDARY OUTCOMES: survival, late hospice referrals (≤ 1 week before death), and dying in preferred place of death.

results216 (56%) of 386 terminally ill cancer patients were receiving palliative chemotherapy at study enrollment, a median of 4.0 months before death. After propensity score weighted adjustment, use of chemotherapy at enrollment was associated with higher rates of cardiopulmonary resuscitation, mechanical ventilation, or both in the last week of life (14% v 2%; adjusted risk difference 10.5%, 95% confidence interval 5.0% to 15.5%) and late hospice referrals (54% v 37%; 13.6%, 3.6% to 23.6%) but no difference in survival (hazard ratio 1.11, 95% confidence interval 0.90 to 1.38). Patients receiving palliative chemotherapy were more likely to die in an intensive care unit (11% v 2%; adjusted risk difference 6.1%, 1.1% to 11.1%) and less likely to die at home (47% v 66%; -10.8%, -1.0% to -20.6%), compared with those who were not. Patients receiving palliative chemotherapy were also less likely to die in their preferred place, compared with those who were not (65% v 80%; adjusted risk difference -9.4%, -0.8% to -18.1%).

conclusionsThe use of chemotherapy in terminally ill cancer patients in the last months of life was associated with an increased risk of undergoing cardiopulmonary resuscitation, mechanical ventilation or both and of dying in an intensive care unit. Future research should determine the mechanisms by which palliative chemotherapy affects end of life outcomes and patients' attainment of their goals.

Indexed as

AdultCritical CareDeathFemaleHospicesHumansMaleMiddle AgedNeoplasmsPalliative CarePatient PreferenceProspective StudiesSurvival AnalysisTerminal CareTerminally Ill

Identifiers

PMID24594868
PMCPMC3942564
OpenAlexW2023888294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.